This paper describes methodological details used by WHO in 2015 to estimate TB incidence, prevalence and mortality. Incidence and mortality are disaggregated by HIV status, age and sex. Methods to derive MDRTB burden indicators are detailed. Four main methods were used to derive incidence: ( i ) case notification data combined with expert opinion about case detection gaps (120 countries representing 51% of global incidence); ( ii ) results from national TB prevalence surveys (19 countries, 46% of global incidence); ( iii ) notifications in highincome countries adjusted by a standard factor to account for underreporting and underdiagnosis (73 countries, 3% of global incidence) and ( iv ) capturerecapture modelling (5 countries, 0.5% of global incidence). Prevalence was obtained from results of national prevalence surveys in 21 countries, representing 69% of global prevalence). In other countries, prevalence was estimated from incidence and disease duration. Mortality was obtained from national vital registration systems of mortality surveys in 129 countries (43% of global HIVnegative TB mortality). In other countries, mortality was derived indirectly from incidence and case fatality ratio.
Introduction
Global targets for reductions in TB disease burden by 2015 were set within the context of the United Nations' Millennium Development Goals (MDGs) 1 . The targets were that TB incidence should be falling, and that TB mortality and prevalence rates should be Estimates of the burden of disease caused by TB and measured in terms of incidence, prevalence and mortality are produced annually by WHO using information gathered through surveillance systems (case notifications and death registrations), special studies (including surveys of the prevalence of disease), mortality surveys, surveys of underreporting of detected TB, indepth analysis of surveillance and other data, expert opinion and consultation with countries.
Historical background
Historically, a major source of data to derive incidence estimates were results from tuberculin surveys conducted in children 4 . Early studies showed the following relationship between the annual risk of infection denoted λ and the incidence of smear positive TB denoted I s+ : one smear positive case infects on average 10 individuals per year for a period of 2 years and a risk of infection of 10 . However, this relationship no longer holds in the × context of modern TB control and in HIV settings 5 . In addition to uncertainty about the relationship between λ and I s+ , estimates of incidence obtained from tuberculin surveys suffer from other sources of uncertainty and bias, including unpredictable diagnostic performance of the tuberculin test 6 , digit preference when reading and recording the size of tuberculin reactions 7 , sensitivity to assumptions about reaction sizes attributed to infection 8 , sensitivity to the common assumption that the annual risk of infection is age invariant, and lastly, sensitivity of overall TB incidence estimates to the assumed proportion of TB incidence that is smear positive.
A first global and systematic estimation exercise led by WHO in the early 1990s estimated that there were approximately 8 million incident TB cases in 1990 (152 × ). The most important sources of × information were case notification data for which gaps in detection and reporting were obtained from expert opinion. In addition, data from 24 tuberculin surveys were translated into incidence and 14 prevalence surveys of TB disease were used.
Incidence TB incidence has never been measured through population based surveys at national level because this would require longterm studies among large cohorts of people (hundreds of thousands), involving high costs and challenging logistics. Notifications of TB cases provide a good proxy indication of TB incidence in countries that have both highperformance surveillance systems (for example, there is little underreporting of diagnosed cases) and where the quality of and access to health care means that few cases remain undiagnosed. In the large number of countries where these criteria are not yet met, better estimates of TB incidence can be obtained from an inventory study. An inventory study is a survey to quantify the level of underreporting of detected TB cases; if certain conditions are met, capturerecapture methods can also be used to estimate TB incidence 11 .
The ultimate goal of TB surveillance is to directly measure TB incidence from national case notifications in all countries. This requires a combination of strengthened surveillance, better quantification of underreporting (i.e. the number of newly diagnosed cases that are missed by surveillance systems) and universal access to health care (to minimize underdiagnosis of cases). A TB surveillance checklist developed by the WHO Global Task Force on TB Impact Measurement defines the standards that need to be met for notification data to provide a direct measure of TB incidence 12 . By August 2015, a total of 38 countries including 16 high TB burden countries (HBCs) had completed the checklist.
Methods currently used by WHO to estimate TB incidence can be grouped into four major categories. Figure 1 shows the distribution of countries according to the four categories:
1. Case notification data combined with expert opinion about case detection gaps (120 countries); 2. Results from national TB prevalence surveys (19 countries); 3. Notifications in highincome countries adjusted by a standard factor to account for underreporting and underdiagnosis (73 countries); 4. Capture recapture modelling (5 countries).
Four main methods
Method 1 Case notification data combined with expert opinion about case detection gaps.
Expert opinion, elicited in regional workshops, national consensus workshops or country missions, is used to estimate levels of underreporting and underdiagnosis.
Trends are estimated using either mortality data, national repeat surveys of the annual risk of infection or exponential interpolation using estimates of case detection gaps for three years. This method was used for 120 countries (Figure 1 ) that accounted for 51% of the estimated global number of incident cases in 2014. The estimation of case detection gaps is essentially based on an indepth analysis of surveillance data; experts provide their educated best guess about the range of the plausible detection gap g where I denotes incidence, N denotes case notifications, f denotes a cubic spline function in countries with large yeartoyear fluctuations in N , or else, the identity function. The incidence series are completed using assumptions about changes in CFR over time in countries with evidence of improvements in TB prevention and care, such as increased detection coverage over time or improved treatment outcomes, ensuring that the following inequality holds where M denotes mortality.
A full description of the methods used in regional workshops where expert opinion was systematically elicited following an indepth analysis of surveillance data is publicly available in a report of the workshop held for countries in the African Region (in Harare, Zimbabwe, December 2010) 13 . In some countries, case reporting coverage changed significantly during the period 19902014 as a result of disease surveillance reforms (e.g. The proportion of cases that were not reported were assumed to follow a Beta distribution, with parameters α and β obtained from the expected value E and variance V using the method of moments 14 , as follows (1) Time series for the period 1990-2014 were built according to the characteristics of the levels of underreporting and underdiagnosis that were estimated for the three reference years. A cubic spline extrapolation of V and E , with knots set at the reference years, was used for countries with lowlevel or concentrated HIV epidemics. In countries with a generalized HIV epidemic, the trajectory of incidence from 1990 to the first reference year (usually 1997) was based on the annual rate of change in HIV prevalence and time changes in the fraction F of incidence attributed to HIV, determined as follows where h is the prevalence of HIV in the general population, ρ is the TB incidence rate ratio among HIVpositive individuals over HIVnegative individuals and ϑ is the prevalence of HIV among new TB cases.
If there were insufficient data to determine the factors leading to timechanges in case notifications, incidence was assumed to follow a horizontal trend going through the most recent estimate of incidence.
Limitations of the method based on eliciting expert opinion about gaps in case detection and reporting included a generally small number of interviewed experts; lack of clarity about vested interests when eliciting expert opinion; lack of recognition of overreporting (due to overdiagnosis, e.g. in some countries of the former Soviet Union implementing a largescale systematic population screening policy that may result in many people with abnormal chest Xray but no bacteriological confirmation of TB disease being notified and treated as new TB cases); incomplete data on laboratory quality and high proportion of patients with no bacteriological confirmation of diagnosis are a potential source of error in estimates. Incidence was estimated using prevalence survey results in 19 countries that accounted for 46% of the estimated global number of incident cases in 2014. Two approaches were used to derive incidence from prevalence. In a first approach, incidence is estimated using measurements from national surveys of the prevalence of TB disease combined with estimates of the duration of disease.
Incidence is estimated as the prevalence of TB divided by the average duration of disease assuming epidemic equilibrium: let N denote the size of a closed population with the number of birth and deaths the same for a period Δ t >0, let C be the number of prevalent TB cases, P the prevalence rate so that P = C / N . Let m denote the rate of exit from the pool of prevalent cases through mortality, spontaneous selfcure or cure from treatment, and I the rate new cases are added to the pool. At equilibrium during the time period Δ t and further assuming exponentially distributed durations d such that Table 1 .
A second approach consists of estimating disease duration using three model compartments: susceptibles ( S ), untreated TB ( U ) and treated TB ( T ). The size of U and T is obtained from the prevalence survey. Transitions from U to T are determined as follows Where I denotes Incidence, μ and θ denote mortality and selfcure or cure (with subscripts u and t indicating untreated and treated cases), respectively, δ denotes the rate of removal from U through detection and treatment. At equilibrium, the above two equations simplify to Disease duration (untreated) is obtained from where is the proportion of incidence that dies or selfcures before treatment. π is assumed distributed uniform with bounds 0 and 0.1. Table 2 shows estimates of incidence from four recent prevalence surveys using this method.
Among limitations of this method is the insufficient power of surveys to estimate the number of prevalent TB cases on treatment with great precision. Further, in most surveys, cases found on treatment during the survey do not have a bacteriological status at onset of treatment documented based on the same criteria as survey cases (particularly when culture is not performed routinely). The method, however, provides more robust estimates of incidence compared with those obtained from expert opinion (method 1). Figure 2 shows recent changes in estimates as new data became available.
As a result of recent survey data in Nigeria and Indonesia, global estimates of incidence increased by about 1 million cases. Time trends, however, were not significantly affected.
In countries with highlevel HIV epidemics that completed a prevalence survey, the prevalence of HIV among prevalent TB cases was found systematically lower than the prevalence of HIV among newly notified TB cases, with an HIV prevalence rate ratio among prevalent TB over notified cases ranging from 0.07 in Rwanda (2012) to 0.5 in Malawi (2013). The HIV rate ratio was predicted from a randomeffects model fitting data from 5 countries (Malawi, Rwanda, Tanzania, Uganda, Zambia) using a restricted maximum likelihood estimator and setting HIV among notified cases as an effect modifier 15 , using the R package metafor 16 ( Figure 3) . The model was then used to predict HIV prevalence in prevalent cases from HIV prevalence in notified cases in African countries that were not able to measure the prevalence of HIV among survey cases.
The above two methods to derive incidence from prevalence are compared in Table 3 . It is not clear which method will perform better. The second method requires a sufficient number of cases on treatment at the time of the survey (as a rule of thumb, at least 30 cases) to generate stable estimates. When both methods can be applied (so far only in lowHIV settings), results from two methods may be combined in a statistical ensemble approach as follows:
The incidence rate obtained using method i is assumed distributed Beta with shape and scale parameters α i +1 and β i +1, respectively, and determined using the method of moments based on equation 3:
The combined probability is then expressed as . The estimate of the surveillance gap in the UK and the Netherlands was assumed time invariant. In Yemen, trends in incidence were derived from results of two consecutive tuberculin surveys 22 . In Egypt and Iraq, trends were derived using methods described in section describing method 1.
HIVpositive TB incidence TB incidence was disaggregated by HIV and CD4 status using the Spectrum software 23 .
WHO estimates of TB incidence were used as inputs to the Spectrum HIV model. The model was fitted to WHO estimates of TB incidence, and then used to produce estimates of TB incidence among people living with HIV disaggregated by CD4 category 24 . A regression method was used to estimate the relative risk (RR) for TB incidence according to the CD4 categories used by Spectrum for national HIV projections 25 .
Spectrum data used the national projections prepared for the UNAIDS Report on the global AIDS epidemic 2015. The model can also be used to estimate TB mortality among
HIVpositive people, the resource requirements associated with recently updated guidance on ART and the impact of ART expansion.
There is no satisfactory way to verify results for TB incidence among people living with HIV when no HIVtesting data in TB are available. A comparative method to disaggregate TB incidence by HIV is shown in annex 2. Providerinitiated testing and counselling with at least 50% HIV testing coverage is the most widely available source of information on the prevalence of HIV in TB patients. However, this source of data is affected by biases, particularly when coverage is closer to 50% than to 100%. As coverage of HIV testing continues to increase globally, biases will decrease.
Disaggregation by age and sex 
Producing estimates of TB incidence among children is challenging primarily due to the lack of well performing diagnostics to confirm childhood TB and the lack of agespecific, nationwide, robust survey and surveillance data.
Prevalence

Populationbased surveys
The best way to measure the prevalence of TB is through national populationbased surveys of TB disease 35, 36 . Data from such surveys are available for an increasing number of countries and were used for 21 countries (Figure 4 ), representing 69% of global prevalence in 2014. Measurements of prevalence are typically confined to the adult population, exclude extrapulmonary cases and do not allow the diagnosis of cases of culturenegative pulmonary TB.
TB prevalence all forms and all ages ( P ) is measured as: bacteriologicallyconfirmed pulmonary TB prevalence ( P p ) among those aged ≥15 measured from national survey ( P a ), adjusted for pulmonary TB in children ( P c ) and the proportion e of extrapulmonary TB all ages where c is the proportion of children among the total country population.
The estimate of overall prevalence P is affected by sampling uncertainty (relative precision is typically about 20%), and uncertainty about e (of note, values for e vary widely among countries with highperformance TB surveillance) and P c . The quality of routine surveillance data to inform levels of pulmonary TB in children and extrapulmonary TB for all ages is often questionable.
Indirect estimates
Indirect estimates of prevalence were calculated by solving equation 3 for P , summing over 4 case categories where the index variable i denotes HIV+ and HIV-, the index variable j denotes treated and nontreated cases, and d denotes the duration of disease.
When there is no direct measurement from a national survey of the prevalence of TB disease, prevalence is the most uncertain of the three TB indicators used to measure disease burden. This is because prevalence is the sum of products of two uncertain quantities, incidence and disease duration. There is scarce empirical data on disease duration (a typically large proportion of bacteriologically confirmed cases detected during TB prevalence surveys did not report symptoms suggestive of TB at the time of survey investigations 34 ). Unless measurements were available from national programmes (for example, Turkey), assumptions of the duration of disease were used as shown in Table 1 . An important limitation is that duration is considered time invariant within case categories.
Mortality
The best sources of data about deaths from TB (excluding TB deaths among
HIVpositive people) are vital registration (VR) systems in which causes of death are coded according to ICD10 (although the older ICD9 and ICD8 classification are still in use in several countries), using ICD10: A15A19 codes, equivalent to ICD9: 010018.
When people with AIDS die from TB, HIV is registered as the underlying cause of death and TB is recorded as a contributory cause. Since one third of countries with VR systems report to WHO only the underlying causes of death and not contributory causes, VR data usually cannot be used to estimate the number of TB deaths in HIVpositive people.
Two methods were used to estimate TB mortality among HIVnegative people:
• direct measurements of mortality from VR systems or mortality surveys (129 countries, in green in Figure 6 ); • indirect estimates derived from multiplying estimates of TB incidence by estimates of the CFR (88 countries). Reports of TB mortality were adjusted upwards to account for incomplete coverage (estimated deaths with no cause documented) and illdefined causes of death (ICD9:
Estimating TB mortality among
B46, ICD10: R00-R99) 38 . It was assumed that the proportion of TB deaths among deaths not recorded by the VR system was the same as the proportion of TB deaths in VRrecorded deaths. For VRrecorded deaths with illdefined causes, it was assumed that the proportion of deaths attributable to TB was the same as the observed proportion in recorded deaths. The adjusted number of TB deaths κ a was obtained from the VR report κ as follows:
where v denotes coverage (i.e. the number of deaths with a documented cause divided by the total number of estimated deaths) and g denotes the proportion of illdefined causes. The uncertainty related to the adjustment was estimated as follows:
The uncertainty calculation does not account for miscoding, such as HIV deaths miscoded as deaths due to TB, except in South Africa.
Missing data between existing adjusted data points were interpolated. Trailing missing values were predicted using exponential smoothing models for time series 39 . A penalized likelihood method based on the insample fit was used for countryspecific model selection. Leading missing values were similarly predicted backwards to 1990.
In 2014, 43% of global TB mortality (excluding HIV) was directly measured from VR or survey data (or imputed from survey or VR data from previous years). The remaining 57% was estimated using the indirect methods described in the next section.
Estimating TB mortality among HIVnegative people from estimates of case fatality rates and TB incidence
In 88 countries lacking VR data of the necessary coverage and quality, TB mortality was estimated as the product of TB incidence and the case fatality rate (CFR) after disaggregation by case type as shown in Table 4 , following a literature review of CFRs by the TB Modelling and Analysis Consortium (TBMAC): (5) where M denotes mortality, I incidence. f u and f t denote CFRs untreated and treated, respectively and the superscript denotes HIV status. T denotes the number of treated TB cases. In countries where the number of treated patients that are not notified (underreporting) is known from an inventory study, the number of notified cases is adjusted upwards to estimate T accounting for underreporting. with VR data tend to be of a higher socioeconomic status compared with countries with no VR data where the indirect approach was used.
Estimating TB mortality among HIVpositive people
TB mortality among HIVpositive is calculated using equation 5, exchanging superscripts with +. The case fatality ratios were obtained in collaboration with the TB Modeling and Analysis Consortium (TBMAC), and are shown in Table 5 . The disaggregation of incident TB into treated and not treated cases is based on the ratio of the point estimates for incident and notified cases, adjusted for underreporting. A single CFR was used for all bootstrapped mortality estimates 24 .
Direct measurements of HIVassociated TB mortality are urgently needed. This is especially the case for countries such as South Africa and Zimbabwe, where national VR systems are already in place. In other countries, more efforts are required to initiate the implementation of sample VR systems as an interim measure. 
Disaggregation of TB mortality by age and sex
In countries with VR or mortality survey data, M 0−14 is directly measured. For the sex disaggregation of TB mortality among adults ( M 15+ ), sexspecific adjusted (for coverage and illdefined causes) number of deaths from VR to estimate mortality rates in men M m and women M w were used. The ratio of these rates r 3 = M m / M w is either directly measured in countries with VR data or imputed in countries without and sexspecific mortality rates are then derived in a manner similar to shown in equation 6.
TB deaths among HIVpositive people were disaggregated by age and sex using the assumption that the child to adult and men to women ratios are the same as the corresponding ratios of AIDS deaths estimated by UNAIDS.
Projections up to 2015
Projections of incidence, prevalence and mortality up to 2015 enable assessment of whether global targets set for 2015 are likely to be achieved at global, regional and country levels. Projections for the year 2015 were made using exponential smoothing models fitted to data from 2007-2014, based on an algorithm that selects the best among models within a family of exponential smoothing models, using a penalized likelihood method as a selection criterion 40 . Point forecasts are computed using the best model with optimized parameters and uncertainty is propagated using analytical methods described in the next section.
Estimation of uncertainty
There are many potential sources of uncertainty associated with estimates of TB incidence, prevalence and mortality, as well as estimates of the burden of HIVassociated TB and MDRTB. These include uncertainties in input data, in parameter values, in extrapolations used to impute missing data, and in the models used. Uncertainty in population estimates was not accounted for. 
Conclusion
The measurement methods described here can be combined to assess tuberculosis incidence, prevalence and mortality, to evaluate progress towards targets for The challenge presented by assessing MDGs achievements has been to measure trends in TB incidence, prevalence, and deaths. The MDGs have now been followed by a set of healthrelated SDG is to "End the epidemics of AIDS, TB, malaria and neglected tropical diseases, and combat hepatitis, waterborne diseases and other communicable diseases". WHO's post2015 global TB strategy, known as the End TB Strategy 44 , also has the goal of ending the global TB epidemic, with corresponding targets of a 90% reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030.
Improved measurements through substantial investments in health information systems, TB surveillance and the broader SDG agenda will provide a firmer basis for monitoring progress towards the End TB Strategy targets and ultimate TB elimination.
Annex 1 Definitions
Incidence is defined as the number of new and recurrent (relapse) episodes of TB (all forms) occurring in a given year. Recurrent episodes are defined as a new episode of TB in people who have had TB in the past and for whom there was bacteriological confirmation of cure and/or documentation that treatment was completed.
Prevalence is defined as the number of TB cases (all forms) at a the middle of the year. Let I and N denote incident cases and the total population, respectively, superscripts + and denote HIV status, ϑ is the prevalence of HIV among new TB cases, h is the prevalence of HIV in the general population and ρ is the incidence rate ratio (HIVpositive over HIVnegative).
The TB incidence rate ratio ρ can be estimated by fitting the following linear model with a slope constrained to 1 Annex 3 Implementation steps
The methods described in the paper were implemented in the following steps:
1. Estimating overall TB incidence after review and cleaning of case notification data; 2. cleaning and adjusting raw mortality data from VR systems and mortality surveys, followed by imputation of missing values in countries with VR or survey data -in some countries, step 1 was updated to account for mortality data; 3. cleaning of measurements of HIV prevalence among TB patients followed by estimating HIVpositive TB incidence using the Spectrum programme and
HIVpositive TB mortality; 4. estimating HIVnegative TB mortality in countries with no VR data followed with an update of step 1 in some countries; 5. reviewing prevalence measurements, adjusting for childhood TB and bacteriologically unconfirmed TB, and estimating prevalence followed with an update of step 1 in some countries; 6. estimating incidence and mortality disaggregated by age and sex and disaggregated by drug resistance status. Figures   Fig. 1 Main method to estimate TB incidence. In the first method, case notification data are combined with expert opinion about case detection gaps (underreporting and underdiagnosis), and trends are estimated using either mortality data, repeat surveys of the annual risk of infection or exponential interpolation using estimates of case detection gaps for three years. For all highincome countries except the Netherlands and the United Kingdom, notifications are adjusted by a standard amount or measures of underreporting from inventory studies, to account for case detection gaps.
Tables
Fig 2.
Estimates of TB incidence obtained indirectly (in blue) based on case notifications and expert opinion about detection and reporting gaps prior to a recent national prevalence survey, and derived from prevalence using survey results (in red), corresponding to the survey year (20122014). The length of segments indicate uncertainty ranges. Countries are presented in the order of the difference between estimates, grouped by continent. Estimates derived from prevalence are more robust. Postsurvey estimates resulted in significant increases in estimated incidence in Nigeria and Indonesia, two countries with large population sizes resulting in a notable impact on global estimates. The often narrow uncertainty ranges of presurvey estimates reflect a certain level of overconfidence of experts asked to estimate plausibility ranges for incidence. The postsurvey estimate in Tanzania is highly uncertain, reflecting data management problems at the time of the survey as well as incomplete laboratory data. ( n =21). In the case of India, data from subnational surveys were pooled to provide a national estimate.
Fig. 6
Countries (in green) for which TB mortality is estimated using measurements from vital registration systems ( n =127) and/or mortality surveys ( n =2) Fig. 7 Comparison of VR mortality (HIVnegative), horizontal axis (log scale) and mortality predicted as the product of incidence and CFR, vertical axis (log scale). Horizontal and vertical segments indicate uncertainty intervals. The dashed red line shows equality. The blue line and associated grey banner show the leastsquared best fit to the data, with a slope not constrained to one.
